中华医学遗传学杂志
中華醫學遺傳學雜誌
중화의학유전학잡지
CHINESE JOURNAL OF MEDICAL GENETICS
2010年
5期
540-545
,共6页
杨壹羚%范宇%郎荣刚%谷峰%付丽
楊壹羚%範宇%郎榮剛%穀峰%付麗
양일령%범우%랑영강%곡봉%부려
乳腺肿瘤%HER2基因%遗传异质性
乳腺腫瘤%HER2基因%遺傳異質性
유선종류%HER2기인%유전이질성
breast neoplasm%HER2 gene%genetic heterogeneity
目的 介绍乳腺癌患者HER2基因扩增的瘤内遗传异质性(genetic heterogeneity,GH)现象,并探讨HER2基因GH与临床病理学参数间的相关性,寻找与HER2基因GH现象密切相关的病理学因素.方法 整理100例浸润性乳腺癌患者分期、组织学分型、分子分型等临床数据,应用免疫组化技术(immunohistochemistry,IHC)检测HER2、雌激素受体α(estrogen peceptor α,ERα)和孕激素受体(progesterone receptor,PR)蛋白表达,用荧光原位杂交(fluorescence in situ hybridization,FISH)技术检测HER2基因扩增情况,并分析HER2基因异质性与临床病理参数间的关系.结果 100例乳腺癌患者中有20%的病例(20/100)存在HER2基因GH现象.在瘤内异质性样本中,扩增细胞所占比例≥25%的样本组其FISH结果阳性率明显高于扩增细胞<25%的样本组(P=0.012).HER2蛋白的表达程度(P=0.004)和ER蛋白表达(P=0.002)与HER2基因GH现象显著相关.结论 HER2基因GH现象最易出现于HER2蛋白轻到中度表达、ER蛋白表达的乳腺癌组织,故而对于具有上述病理学特征的患者进行FISH检测时应特别注意GH现象,以免遗漏阳性细胞或者只计数阳性细胞,而给出不准确的FISH结果.
目的 介紹乳腺癌患者HER2基因擴增的瘤內遺傳異質性(genetic heterogeneity,GH)現象,併探討HER2基因GH與臨床病理學參數間的相關性,尋找與HER2基因GH現象密切相關的病理學因素.方法 整理100例浸潤性乳腺癌患者分期、組織學分型、分子分型等臨床數據,應用免疫組化技術(immunohistochemistry,IHC)檢測HER2、雌激素受體α(estrogen peceptor α,ERα)和孕激素受體(progesterone receptor,PR)蛋白錶達,用熒光原位雜交(fluorescence in situ hybridization,FISH)技術檢測HER2基因擴增情況,併分析HER2基因異質性與臨床病理參數間的關繫.結果 100例乳腺癌患者中有20%的病例(20/100)存在HER2基因GH現象.在瘤內異質性樣本中,擴增細胞所佔比例≥25%的樣本組其FISH結果暘性率明顯高于擴增細胞<25%的樣本組(P=0.012).HER2蛋白的錶達程度(P=0.004)和ER蛋白錶達(P=0.002)與HER2基因GH現象顯著相關.結論 HER2基因GH現象最易齣現于HER2蛋白輕到中度錶達、ER蛋白錶達的乳腺癌組織,故而對于具有上述病理學特徵的患者進行FISH檢測時應特彆註意GH現象,以免遺漏暘性細胞或者隻計數暘性細胞,而給齣不準確的FISH結果.
목적 개소유선암환자HER2기인확증적류내유전이질성(genetic heterogeneity,GH)현상,병탐토HER2기인GH여림상병이학삼수간적상관성,심조여HER2기인GH현상밀절상관적병이학인소.방법 정리100례침윤성유선암환자분기、조직학분형、분자분형등림상수거,응용면역조화기술(immunohistochemistry,IHC)검측HER2、자격소수체α(estrogen peceptor α,ERα)화잉격소수체(progesterone receptor,PR)단백표체,용형광원위잡교(fluorescence in situ hybridization,FISH)기술검측HER2기인확증정황,병분석HER2기인이질성여림상병리삼수간적관계.결과 100례유선암환자중유20%적병례(20/100)존재HER2기인GH현상.재류내이질성양본중,확증세포소점비례≥25%적양본조기FISH결과양성솔명현고우확증세포<25%적양본조(P=0.012).HER2단백적표체정도(P=0.004)화ER단백표체(P=0.002)여HER2기인GH현상현저상관.결론 HER2기인GH현상최역출현우HER2단백경도중도표체、ER단백표체적유선암조직,고이대우구유상술병이학특정적환자진행FISH검측시응특별주의GH현상,이면유루양성세포혹자지계수양성세포,이급출불준학적FISH결과.
Objective To introduce the College of American Pathologists/American College of Medical Genetics Cytogenetics Resource Committee criteria for genetic heterogeneity (GH) in HER2 testing, and investigate the clinicopathological significance of HER2 genetic heterogeneity in invasive breast cancer. Methods The clinical parameters of 100 cases of invasive breast carcinomas were collected. HER2 expression level and HER2 gene copy number in formalin-fixed and paraffin embedded tumor samples were detected by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), and the relationship between HER2 gene GH and clinicopathological characteristics were analyzed. Results Among the 100 patients, HER2 gene GH was observed in 20 (20%) cases. When the number of HER2 amplified cells was more than 25 %, the frequencies of FISH positive were higher than those cases with less than 25 % HER2 amplified cells. The results showed that HER2 gene GH was associated with the degree of HER2 protein expression (P= 0. 004), and ER expression (P = 0. 002). Conclusion HER2 gene GH may be correlated with the HER2 protein IHC 1+/2+, and ER expression in breast carcinoma. It is important for doctors to avoid ignoring or only counting FISH positive cells leading to incorrect diagnosis for these patients.